Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104215 | 0.95 | FFAR1 (0.46) | FFAR1MAPTS1PR1PTPN1ADRB3 | |
| SCHEMBL9101504 | 0.94 | FFAR1 (0.50) | FFAR1MAPTS1PR1PTPN1ADRB3 | |
| SCHEMBL9101572 | 0.92 | FFAR1 (0.50) | FFAR1MAPTS1PR1PTPN1ADRB3 | |
| SCHEMBL9101236 | 0.90 | S1PR1 (0.48) | FFAR1S1PR1PTPN1ADRB3S1PR3 | |
| SCHEMBL9110187 | 0.84 | MAPT (0.48) | FFAR1MAPTS1PR1PTPN1ADRB3 | |
| SCHEMBL9888455 | 0.81 | FFAR1 (0.54) | FFAR1S1PR1PTPN1S1PR3SMPD1 | |
| SCHEMBL9100530 | 0.81 | FFAR1 (0.45) | FFAR1MAPTS1PR1PTPN1S1PR3 | |
| SCHEMBL9111175 | 0.81 | S1PR1 (0.60) | S1PR1S1PR3 | |
| SCHEMBL9103709 | 0.79 | S1PR1 (0.55) | FFAR1S1PR1PTPN1ADRB3S1PR3 | |
| SCHEMBL28807635 | 0.79 | PTPN1 (0.48) | FFAR1S1PR1PTPN1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646022-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| US-8486918-B2 | Phenyl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor | ALLERGAN, INC. (US) | 2013-07-16 | — | — | US | claimed |
| WO-2012074732-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120142745-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | claimed |
| EP-2646022-B1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646022-B1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646022-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8486918-B2 | Phenyl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor | ALLERGAN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486918-B2 | Phenyl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor | ALLERGAN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486918-B2 | Phenyl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor | ALLERGAN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2012074732-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012074732-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142745-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142745-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142745-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142745-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | FFAR1 25/4885MAPT 2626/4885S1PR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.